Hualan Biological Vaccine Inc. (SHE:301207)
China
· Delayed Price · Currency is CNY 16.52
+0.19 (1.16%)
May 16, 2025, 2:45 PM CST
Hualan Biological Vaccine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Net Income | 199.7 | 205.52 | 859.97 | 519.63 | 620.97 | 924.91 | Upgrade
|
| Depreciation & Amortization | 140.37 | 140.37 | 140.33 | 135.43 | 68.93 | 40.85 | Upgrade
|
| Other Amortization | 1.68 | 1.68 | 4.53 | 6.15 | 1.55 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.14 | 0.14 | 0.2 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.24 | 0.24 | 0.25 | -0.58 | 1 | 0.33 | Upgrade
|
| Loss (Gain) From Sale of Investments | -100.37 | -100.37 | -110.17 | -72.45 | -38.01 | -9.91 | Upgrade
|
| Provision & Write-off of Bad Debts | -9.4 | -9.4 | 21.33 | 28.77 | 1.04 | 43.47 | Upgrade
|
| Other Operating Activities | -12.97 | 80.23 | 101.28 | 162.54 | 146.32 | 35.02 | Upgrade
|
| Change in Accounts Receivable | 884.47 | 884.47 | -224.19 | -380.76 | 89.38 | -906.3 | Upgrade
|
| Change in Inventory | -97.32 | -97.32 | -101.23 | -211.49 | -195.39 | -20.17 | Upgrade
|
| Change in Accounts Payable | -642.07 | -642.07 | 170.28 | 117.16 | -116.66 | 669.17 | Upgrade
|
| Change in Other Net Operating Assets | -4.28 | -4.28 | 26.04 | 5.98 | 0.48 | 0.06 | Upgrade
|
| Operating Cash Flow | 369.02 | 468.04 | 888.02 | 288.66 | 569.33 | 693.71 | Upgrade
|
| Operating Cash Flow Growth | -53.40% | -47.29% | 207.64% | -49.30% | -17.93% | 152.22% | Upgrade
|
| Capital Expenditures | -31.05 | -51.6 | -62.6 | -92.65 | -636.06 | -532.28 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.04 | 0.09 | 0.31 | - | 0 | Upgrade
|
| Investment in Securities | -109.34 | -94.76 | -711.21 | -1,712 | -479 | -233.76 | Upgrade
|
| Other Investing Activities | 91.51 | 85.23 | 52.6 | 48.37 | 23.19 | 12.72 | Upgrade
|
| Investing Cash Flow | -48.88 | -61.08 | -721.11 | -1,756 | -1,092 | -753.33 | Upgrade
|
| Short-Term Debt Issued | - | - | 300 | 300 | 800 | 250 | Upgrade
|
| Total Debt Issued | - | - | 300 | 300 | 800 | 250 | Upgrade
|
| Short-Term Debt Repaid | - | - | -300 | -500 | -500 | -50 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | -1.08 | -1.1 | - | Upgrade
|
| Total Debt Repaid | - | - | -300 | -501.08 | -501.1 | -50 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | -201.08 | 298.9 | 200 | Upgrade
|
| Issuance of Common Stock | 16.28 | 16.28 | - | 2,276 | - | - | Upgrade
|
| Repurchase of Common Stock | -106.79 | -106.79 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -363.46 | -334.32 | -120 | -90.88 | -12.77 | -4.59 | Upgrade
|
| Other Financing Activities | - | - | -6.08 | -31.57 | - | -59.72 | Upgrade
|
| Financing Cash Flow | -453.97 | -424.82 | -126.09 | 1,952 | 286.13 | 135.69 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.02 | -0.08 | 0.11 | - | - | - | Upgrade
|
| Net Cash Flow | -133.8 | -17.95 | 40.94 | 485.25 | -236.4 | 76.08 | Upgrade
|
| Free Cash Flow | 337.98 | 416.45 | 825.42 | 196.01 | -66.73 | 161.43 | Upgrade
|
| Free Cash Flow Growth | -53.31% | -49.55% | 321.10% | - | - | 23.09% | Upgrade
|
| Free Cash Flow Margin | 30.23% | 36.93% | 34.24% | 10.74% | -3.65% | 6.65% | Upgrade
|
| Free Cash Flow Per Share | 0.57 | 0.70 | 1.37 | 0.33 | -0.12 | 0.30 | Upgrade
|
| Cash Interest Paid | - | - | 6.08 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 104.59 | 151.5 | 192.05 | 172.31 | 296.12 | 196.8 | Upgrade
|
| Levered Free Cash Flow | 231.97 | 783.91 | 234.5 | -48.25 | -209.35 | 51.01 | Upgrade
|
| Unlevered Free Cash Flow | 235.77 | 787.73 | 238.3 | -41.57 | -201.03 | 52.26 | Upgrade
|
| Change in Net Working Capital | -72.86 | -642.47 | 421.75 | 405.56 | 55.63 | 115.53 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.